Abstract
Sacubitril/valsartan improves mortality and morbidity in patients with heart failure with reduced ejection fraction. However, its impact on right heart failure remains unknown. We experienced a 70-year-old man who was started on sacubitril/valsartan to treat his right heart failure with moderate tricuspid regurgitation. Following the 3-month sacubitril/valsartan treatment, a functional and geological improvement was observed in the right heart as well as amelioration of his congestive symptoms. Sacubitril/valsartan might improve right heart failure in addition to conventionally-proven left heart failure. Further large-scale studies are warranted to validate our findings.
| Original language | English |
|---|---|
| Pages (from-to) | 932-934 |
| Number of pages | 3 |
| Journal | International Heart Journal |
| Volume | 62 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2021 |
Keywords
- ARNI
- Chronic heart failure
- Neprilysin inhibitor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine